Group 1 - The company, Shandong Xinhua Medical Instrument Co., Ltd., has decided to terminate the acquisition of a 36.1913% stake in Wuhan Zhongzhi Biotechnology Co., Ltd. due to the expiration of the delivery deadline as stipulated in the share transfer agreement [2][3]. - The termination was agreed upon after friendly negotiations with all parties involved, including Shenzhen Meijian Electronic Technology Development Co., Ltd. and others, leading to the signing of a supplementary agreement [3]. - The company has not made any payments related to the acquisition, and the termination will not adversely affect its current operating performance or financial status [4]. Group 2 - The company expressed its commitment to continue seeking development opportunities and enhancing its core competitiveness despite the termination of the acquisition [4]. - The company apologized for any inconvenience caused to investors and expressed gratitude for their ongoing support [4].

然而，交易从一开始便伴随估值争议。以2024年5月31日为评估基准日，中帜生物股东权益账面值 8725.52万元，评估值达4.61亿元，增值率高达428.52%，预计产生商誉1.02亿元。这一高溢价引发市场 质疑，在审议该次收购议案时，公司两名董事更投出弃权票，提出"此次收购高估值带来高风险，且无 业绩承诺保证措施做支撑"等原因，直指标的业绩波动与整合不确定性。 从财务数据看，中帜生物的盈利稳定性存在隐忧。2023年，公司实现营业收入1.2亿元、净利润1563.53 万元，但到了2025年上半年则亏损1179.61万元。与此同时，新华医疗自身业绩亦面临压力，2025年前 三季度营收69.78亿元，同比下降6%；归母净利润4.34亿元，同比下降29.61%，公司或在现金流管理与 战略资源分配上更趋审慎。 行业环境的变化进一步加剧了交易的不确定性。2025年，体外诊断行业迎来政策密集调整期：医保支付 方式改革深化，医疗机构控费意愿显著增强；国家药监局发布《关于优化全生命周期监管支持高端医疗 器械创新发展的举措》，支持高端诊断技术产品的研发；六部门联合印发《关于增强消费品供需适配性 进一步促进消费的实施方案》，支持 ...

Core Viewpoint - Xinhua Medical's four-limb rehabilitation training device features a precise linkage structure, diverse training modes, and strong adaptability, providing high cost-performance due to large-scale production and nationwide after-sales service network with efficient response and full-cycle support [1] Group 1 - The four-limb rehabilitation training device utilizes a precise linkage structure [1] - The training modes are diverse and adaptable [1] - The pricing benefits from large-scale production, offering high cost-performance [1] Group 2 - The after-sales service covers a nationwide network [1] - The company ensures efficient response and full-cycle support for its products [1]

证券日报网讯2月6日，新华医疗（600587）在互动平台回答投资者提问时表示，直线加速器、大孔径 CT、后装治疗机均为公司放疗核心优势产品，公司将依规参与符合资质的医疗设备招标项目，积极拓 展市场，为公司创造更多价值。 ...

证券日报网讯2月6日，新华医疗（600587）在互动平台回答投资者提问时表示，公司大孔径CT拥有大 孔径、低剂量、精准成像等技术优势，可与放疗设备形成方案协同，性价比与本土化服务优于进口品 牌，目前正依托政策与临床推广加快国产替代。 ...

新华医疗表示，自签订《股份转让协议》以来，公司积极与交易对方就收购事项履行相关审批程序。截 至公告之日，《股份转让协议》约定的交割期限已过，经与交易各方友好协商，决定终止《股份转让协 议》。鉴于本次收购的付款先决条件未达成，公司未支付任何款项，且标的股份非因交易任何一方原因 未能按期交割，公司不存在违约情形。本次收购的终止不会对公司现有经营业绩及财务状况产生不利影 响，不存在损害公司及全体股东利益的情形。公司将努力做好经营管理，不断完善公司发展战略，寻求 更多的发展机会，提升公司核心竞争力，推动公司持续健康发展，争取以更好的业绩回报全体股东。 北京商报讯（记者 丁宁）2月6日晚间，新华医疗（600587）发布公告称，决定终止收购武汉中帜生物 科技股份有限公司（简称"中帜生物"）36.1913%的股权。 ...

证券日报网讯 2月6日，新华医疗发布公告称，公司于2024年12月30日召开第十一届董事会第十六次会 议审议通过了《关于现金收购武汉中帜生物科技股份有限公司36.1913%股权的议案》，公司拟收购武 汉中帜生物科技股份有限公司（简称"中帜生物"）36.1913%的股权（简称"标的股份"）。自签订《股份 转让协议》以来，公司积极与交易对方就收购事项履行相关审批程序。截至本公告之日，《股份转让协 议》约定的交割期限已过，经与交易各方友好协商，决定终止《股份转让协议》。公司与深圳市美健电 子科技发展有限公司、深圳市美康信息科技发展有限公司、丁野青、王占宝达成一致意见并签订了《股 份转让协议之补充协议》，同时向上海盛宇黑科创业投资中心（有限合伙）、深圳喜朋私募股权投资基 金合伙企业（有限合伙）、连庆明、庄金辉、董燕、刘卫兵发送了《股份转让协议终止通知函》，终止 此次收购事项。未来，在市场拓展、技术研发等领域，各方将继续保持开放协作的态度，共谋发展机 遇。 （文章来源：证券日报） ...

Group 1 - ZTE Corporation plans to invest 200 million RMB to subscribe to the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund, focusing on areas supported by national policies such as new generation information technology and biotechnology [1] - Huayi Jewelry's subsidiary has reported overdue loans totaling 200 million RMB due to tight liquidity, with a cumulative overdue principal of 254 million RMB [2] - Guangzhou Baiyunshan Pharmaceutical's subsidiary has received approval for the consistency evaluation of Alfacalcidol soft capsules, which are used to treat calcium metabolism disorders [3] Group 2 - Kunming Pharmaceutical Group reported a 21.72% decline in revenue to 6.577 billion RMB and a 46% drop in net profit to 350 million RMB for 2025 [4] - Jiantou Energy's application for a specific stock issuance has been approved by the Shenzhen Stock Exchange [5] - Jinchuan Titanium Industry's subsidiary has temporarily suspended its sulfuric acid production due to reduced demand [6] Group 3 - Kelun Pharmaceutical's subsidiary has received approval for a new indication for its antibody-drug conjugate, which is used to treat advanced hormone receptor-positive breast cancer [7] - Fawer Co., Ltd. has completed the relocation of its Chongqing Yuantai Shock Absorber Company and commenced production [8] - Jiuzhoutong's subsidiary has received acceptance for the listing application of Betahistine Hydrochloride tablets [9] Group 4 - Zhongguancun plans to build a traditional Chinese medicine and raw material drug production base in Jiamusi City, Heilongjiang Province [11] - China Wuyi announced that part of its land in Kenya has been requisitioned by the government, with compensation of approximately 6.25 million RMB [12] - Times Electric reported a 15.46% increase in revenue to 28.761 billion RMB and a 10.88% increase in net profit to 4.105 billion RMB for 2025 [13] Group 5 - Top Cloud Agriculture's shareholder has received regulatory measures from the Zhejiang Securities Regulatory Bureau for failing to timely disclose shareholding changes [14] - Xinwanda's subsidiary has reached a settlement in a lawsuit involving over 2.314 billion RMB, with an estimated impact of 500 to 800 million RMB on net profit for 2025 [15] - Dongrui Co., Ltd. reported a 25.19% increase in pig sales revenue in January, totaling 214 million RMB [16] Group 6 - Tianjin Tianshi reported a 3.08% decline in revenue to 8.236 billion RMB, while net profit increased by 15.68% to 1.105 billion RMB for 2025 [17] - Wantong Expressway plans to invest approximately 5.42 billion RMB in the renovation and expansion of the Lianhuo Expressway [18] - Qiaoyin Co., Ltd. has pre-qualified for a sanitation integration service project worth approximately 73.8 million RMB [20] Group 7 - Jindi Co., Ltd. plans to acquire 100% equity of Yuni Precision for 116 million RMB, focusing on precision stamping products [21] - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties [22] - Tongde Chemical has had some assets frozen due to a financing lease dispute [23] Group 8 - Zhongli Co., Ltd. is establishing an industrial fund with a total commitment of approximately 408.76 million RMB, focusing on new materials and artificial intelligence [24] - Tianbang Food reported a 9.93% increase in pig sales revenue in January, totaling 674 million RMB [25] - New Hope reported a 10.03% decrease in pig sales revenue in January, totaling 1.628 billion RMB [26] Group 9 - Tainkang's subsidiary has received a drug registration certificate for Minoxidil topical solution [27] - Lihua Co., Ltd. reported a 9.8% increase in chicken sales revenue in January, totaling 1.289 billion RMB [28] - Guojitong General reported a 45.71% increase in net profit to 58.52 million RMB for 2025 [29] Group 10 - Zhixin Co., Ltd. plans to invest up to 1.1 billion RMB in an automotive stamping and welding parts project [30] - Chuangyuan Technology's subsidiary has pre-qualified for a National Grid project worth approximately 94.77 million RMB [31] - Lisheng Pharmaceutical's adenine phosphate raw material has passed the listing application [32] Group 11 - Tongguang Cable's subsidiary has pre-qualified for a National Grid project worth approximately 108 million RMB [33] - Zhenghong Technology reported a 7.74% increase in pig sales revenue in January, totaling 14.35 million RMB [34] - Pengding Holdings reported a 0.07% decrease in consolidated revenue in January, totaling 2.701 billion RMB [35] Group 12 - Hongri Pharmaceutical has received approval for clinical trials of its injectable drug for acute pancreatitis [36][37] - Xinhua Medical has decided to terminate the acquisition of a 36.19% stake in Wuhan Zhongzhi Biotechnology [38] - Tianyu Bio reported an 11.23% decrease in pig sales revenue in January, totaling 54.29 million RMB [39]

格隆汇2月6日丨新华医疗(600587.SH)公布，自签订《股份转让协议》以来，公司积极与交易对方就收 购事项履行相关审批程序。截至本公告之日，《股份转让协议》约定的交割期限已过，经与交易各方友 好协商，决定终止《股份转让协议》。公司与深圳市美健电子科技发展有限公司、深圳市美康信息科技 发展有限公司、丁野青、王占宝达成一致意见并签订了《股份转让协议之补充协议》，同时向上海盛宇 黑科创业投资中心（有限合伙）、深圳喜朋私募股权投资基金合伙企业（有限合伙）、连庆明、庄金 辉、董燕、刘卫兵发送了《股份转让协议终止通知函》，终止此次收购事项。未来，在市场拓展、技术 研发等领域，各方将继续保持开放协作的态度，共谋发展机遇。 ...

二、终止股权收购的原因 证券代码：600587 证券简称：新华医疗 公告编号：临 2026-009 山东新华医疗器械股份有限公司 关于终止收购武汉中帜生物科技股份有限公司 36.1913%股权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、交易情况概述 山东新华医疗器械股份有限公司（以下简称"公司"或"新华医疗"）于 2024 年 12 月 30 日召开第十一届董事会第十六次会议审议通过了《关于现金收购武汉中 帜生物科技股份有限公司 36.1913%股权的议案》，公司拟收购武汉中帜生物科技 股份有限公司（以下简称"中帜生物"）36.1913%的股权（以下简称"标的股份"）， 详见公司于 2024 年 12 月 31 日在上海证券交易所网站（www.sse.com.cn ）披露的《新华医疗第十一届董事会第十六次会议决议公告》（公告编号：临 2024-043）、《新华医疗关于收购武汉中帜生物科技股份有限公司 36.1913%股权 的公告》（公告编号：临 2024-045）。 自签订《股份转让协议》以来，公司积极与 ...